LMR Partners’s Pyxis Oncology PYXS Stock Holding History

LMR Partners’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-77,300	Closed	-$121K	–	1589
2024 Q4	$121K	Sell	77,300 -2,700	-3%	-$7.79K	﹤0.01%	983
2024 Q3	$294K	Buy	+80,000	New	+$280K	﹤0.01%	916

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

LMR Partners's PYXS Position: Q1 2025 in Review

LMR Partners sold out of Pyxis Oncology (PYXS) in Q1 2025, closing a stake of 77,300 shares — an estimated $121K sold.

LMR Partners first reported a position in PYXS in Q3 2024 and held it in 2 quarters. The position peaked at $294K in Q3 2024. 88 funds tracked by Wall St. Rank hold PYXS as of Q1 2025.

LMR Partners reported no remaining Pyxis Oncology position as of Q1 2025 after selling out during the quarter.
LMR Partners sold 77,300 Pyxis Oncology shares in Q1 2025, an estimated $121K.
LMR Partners first reported a position in Pyxis Oncology in Q3 2024 and held it in 2 quarters.
LMR Partners's Pyxis Oncology position peaked at $294K in Q3 2024.
88 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.